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Objectives: To identify published cost-effectiveness analyses and health technol-
ogy assessment (HTA) submissions for treatments in chronic heart failure (CHF) to 
inform future cost-effectiveness modeling in CHF. MethOds: A systematic review 
was performed. Literature searches were conducted in MEDLINE, EMBASE, EconLit, 
and the Cochrane Library, with supplementary hand searching of conferences and 
HTA websites. Eligible studies had to report on cost-effectiveness outcomes in 
adults with CHF and/or heart failure with reduced ejection fraction, treated with 
angiotensin-converting enzyme inhibitors, beta-blockers, mineralocorticoid recep-
tor antagonists, angiotensin receptor blockers, or ivabradine. Results: Sixty-six 
publications met the inclusion criteria, representing 63 distinct analyses. Of these, 
53 reported their MethOds: 20 were statistical analyses of individual patient 
data, while 33 used decision-analytic modeling. Structures were most commonly 
described as being Markov (n= 27) but the methods were heterogeneous. The health 
states most frequently employed were ‘alive’ or ‘dead’, with outcomes such as hos-
pitalization or New York Heart Association (NYHA) class distribution most com-
monly considered as a partition of the ‘alive’ state. Other health states considered 
were often based on NYHA class, hospitalizations, and major CV events. Different 
approaches to modeling the effects of interventions on mortality were used; treat-
ment effects were applied to cardiovascular (CV) mortality and all-cause mortality 
in nine and 20 studies (among the 33 decision-analytic models), respectively. Across 
included studies, the time horizon ranged from within-trial to lifetime. Outcomes 
were frequently sensitive to baseline risks of mortality and hospitalization, rela-
tive efficacy of interventions, and unit costs of interventions. cOnclusiOns: The 
studies identified were heterogeneous with respect to their approaches; this may 
be due to the preference of payers in different jurisdictions. However, the identified 
literature suggests mortality and hospitalization are the key determinants of the 
cost-effectiveness of treatment for CHF.
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Objectives: Bleeding during complex cardiac surgery is associated with several 
negative clinical outcomes. Fibrinogen concentrate (FC) is a coagulation factor 
concentrate that may positively affect these clinical outcomes. The objective of 
this study was to compare health economic outcomes between using a hemostatic 
therapy protocol with FC and a protocol without FC during complex cardiac sur-
gery. MethOds: The input data of the model was based on a systematic literature 
search, and interviews with experts. Costs were retrieved from national databases. 
The primary effectiveness parameters were the number of blood transfusions 
avoided and the amount of blood loss avoided. One-way and probabilistic sensitiv-
ity analyses (PSA) were performed to test the robustness of results. Results: Five 
studies were included, representing 143 patients. The incremental costs per blood 
transfusion avoided were € 63 and per unit blood loss avoided € 2.4. The average 
number of blood transfusions reduced with 10 units per patient [95% CI: 8 - 12] and 
blood loss with 391mL/12hrs [95%CI: 81mL/12hrs – 711mL/12hrs] in the with FC 
protocol compared to the without FC protocol, whilst costs slightly increased (+€ 611 
[95%CI: € -2,210 - € 3,399]). The FC protocol reduced the number of blood transfusions 
and blood loss in 100% of the simulations of the PSA, and reduced these clinical 
outcomes and costs in 33.3%. The FC dosage was the main cost driver in the model. 
The FC protocol would be cost-saving if lower FC dosages were used (e.g. 2 or 4 
grams instead of 6.4 grams), or if costs of side effects were included (transfusion 
related lung injury and renal failure). cOnclusiOns: Our study indicates that a 
hemostatic therapy protocol with FC is cost-effective in complex cardiovascular 
surgery, leading to better clinical outcomes with minimal incremental costs. Future 
studies need to provide clinical evidence that a lower dosage of FC will still suffice 
to ensure similar health outcomes.
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Objectives: Determine the most cost-effective, licensed, first-line anticoagulant 
for the prevention of ischemic stroke in patients with non-valvular atrial fibril-
lation (AF) in England and Wales from the perspective of the UK National Health 
Service. MethOds: We developed a cost-effectiveness model based on a review of 
previous models and expert clinical opinion. We compared warfarin (International 
Normalized Ratio 2-3) with novel oral anticoagulants (NOACs) apixaban (5mg bd), 
dabigatran (150mg bd), edoxaban (60mg od) and rivaroxaban (20mg od), over 30 
years post treatment initiation. Parameters were informed by a systematic litera-
ture review and competing risks network meta-analysis for comparative efficacy 
and safety of the anticoagulants and baseline hazard of warfarin. Utilities and 
resource use were estimated from the literature. Our model estimated total costs, 
Quality Adjusted Life Years (QALYs), and incremental net benefit relative to war-
farin. Results: At a willingness-to-pay threshold of £20,000 per QALY, all NOACs 
have positive expected incremental net benefit compared to warfarin, suggest-
ing they may be a cost effective use of NHS resources. Apixaban (5mg bd) has the 
highest expected incremental net benefit (£7533), followed by rivaroxaban (£6365), 
edoxaban (£5279) and dabigatran (£5279). Apixaban is the only NOAC for which 
the 95% credible interval around incremental net benefit is positive, suggesting 
a higher degree of certainty that Apixaban is cost-effective compared with war-
farin than for the other NOACs. These conclusions also hold at the higher thresh-
transition probabilities. We assigned costs and health outcomes to each health 
state to estimate the cost per quality-adjusted life year (QALY). Analyses were made 
from the National Health System (NHS) perspective, including direct healthcare 
costs (2015 euros) and a discount rate of 3% was applied to both costs and health 
outcomes. Time horizon was patient lifetime’s expectancy. We performed various 
sensitivity analyses, including probabilistic one, to assess the robustness of the 
results. Results: Compared to standard treatment, edoxaban was cost-effective 
using the different time horizons (3, 6 and 12 months). At 12 months, edoxaban 
showed a slight increment in treatment costs of 152€ per VTE patient, but an 
increase in QALYs and Life Years Gained (LYG) resulting in cost-effective results. 
Edoxaban demonstrated incremental cost-effectiveness ratios (ICERs) of 6,333 € 
per QALYs and 10,857 € per LYG compared with standard treatment at 12 months. 
The results of the probabilistic sensitivity analysis confirmed the efficiency of 
edoxaban. cOnclusiOns: From the Spanish NHS perspective, edoxaban is a cost-
effective alternative for the treatment of VTE patients compared to standard therapy.
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Objectives: Screening for atrial fibrillation (AF) has been advocated as a way to 
reduce the burden of stroke. Good quality evidence suggests that while oppor-
tunistic and systematic screening produce comparable increases in AF detection, 
opportunistic screening does so at significantly less cost. However, uncertainty 
about the risk profile of undiagnosed patients and the overall cost-effectiveness 
of screening has meant that no national AF screening programmes have as yet 
been implemented. The aim of this study was to evaluate the cost-effectiveness 
of a prospective national AF screening programme on stroke incidence and sever-
ity. MethOds: We conducted a cost-utility analysis of opportunistic pulse palpation 
(with confirmatory ECG) in primary care in Ireland, comparing different start ages 
and screening frequencies. We also examined the implications of subclinical AF car-
rying a different risk of stroke than diagnosed AF, as well as the potential impact of 
increased use of new oral anticoagulant (NOACs) on the cost-effectiveness of screen-
ing. The primary analysis was conducted from the perspective of the publicly funded 
health system, using a time horizon of 25 years and a discount rate of 5% for costs 
and benefits. Results: Annual screening from age 65 is associated with an ICER of 
€ 20,271/QALY, with an 83% probability of being cost-effective at a willingness-to-pay 
threshold of € 45,000/QALY. Older start ages and longer screening intervals are likely 
to improve the cost-effectiveness of the intervention, but result in less absolute 
benefit. Annual screening from age 65 would not be cost-effective at a threshold 
of € 45,000/QALY if the relative risk of stroke and systemic embolism in subclinical 
AF is less than 0.84. Changes in usage rates of NOACs are unlikely to significantly 
affect the cost-effectiveness of screening. cOnclusiOns: Opportunistic screening 
in primary care increases AF detection, reduces stroke incidence, and is likely to be 
cost-effective using conventional willingness-to-pay thresholds.
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Objectives: To evaluate the cost-effectiveness of trimetazidine (TMZ) as add-on 
therapy to standard-of-care (SoC) compared to SoC alone in patients with chronic 
stable angina who did not respond adequately to first line therapy with beta-block-
ers, nitrates or calcium channel antagonists, in Greece. MethOds: A Markov model 
with monthly cycles and 1-year time horizon was developed to assess the compara-
tors. The analysis was conducted from a third-party payer perspective. The clinical 
inputs and utility values were extracted from the published literature. Cost inputs 
considered in the model include anti-anginal drug-acquisition costs, hospitalization 
costs (with and without vascular interventions), and monitoring costs that encom-
pass outpatient visits, laboratory and diagnostic tests. Resource consumption data 
were obtained from local experts, using a questionnaire developed for the purpose 
of the study. These were combined with unit cost data obtained from official sources. 
All costs reflect the year 2014. Cost effectiveness was assessed by calculating the 
incremental cost effectiveness ratio (ICER). Probabilistic sensitivity analysis (PSA) 
was performed to account for uncertainty and variation in the input parameters of 
the model. Results: The analysis showed that the cost of TMZ plus SoC was € 1,055 
versus € 1,040 for SoC alone. In terms of health outcomes, TMZ plus SoC was associ-
ated with 0.617 QALYs versus 0.614 QALYs for SoC alone. The incremental analysis 
resulted in an ICER of € 4,148 per QALY gained. PSA revealed that the probability of 
TMZ plus SoC being cost-effective compared with SoC was 95%, at a threshold of 
€ 34,000 per QALY gained (twice the average annual income). cOnclusiOns: The 
results indicate that TMZ as add–on treatment is a highly cost-effective option for 
the symptomatic treatment of patients with chronic stable angina in Greece when 
compared to SoC alone.
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ses). Results: Sixteen economic analyses were included; all studies used deci-
sion-tree structures to model acute prophylaxis, and 13 included a chronic-phase 
Markov module to capture long-term complications and recurrent VTE events. The 
model structures generally captured the important events needed to accurately 
estimate differences in costs and outcomes between different treatment strate-
gies. Eleven studies included rivaroxaban, 9 studies included dabigatran, 3 studies 
included apixaban, and no studies included edoxaban. The analyses that compared 
a NOAC with low molecular-weight heparin (LMWH) predominantly resulted in 
the NOAC dominating LMWH for patients with both THR and TKR. The results of 
analyses that compared NOACs with each other suggested that dabigatran is the 
least cost-effective option. There is limited evidence directly comparing rivaroxaban 
with apixaban, but our results suggested that rivaroxaban dominates apixaban for 
patients with TKR in the United Kingdom. cOnclusiOns: Economic analyses of 
NOACs for primary VTE prophylaxis following THR and TKR surgeries show reason-
able consistency in the model structures used and events captured. The results 
strongly suggest that NOACs are cost-effective alternatives to LMWH. Dabigatran 
appears to be the least cost-effective NOAC. However, more research is needed to 
assess the cost-effectiveness of apixaban and edoxaban.
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Objectives: Iron deficiency (ID) is highly prevalent in chronic heart failure (CHF) 
patients and imposes a significant disease burden for CHF patients with enormous 
impact on their outcome. Two pivotal studies (FAIR-HF and CONFIRM-HF) showed 
that the iron deficiency with ferric carboxymaltose (FCM), an i.v. iron, results in 
clinical meaningful benefits. The purpose of this study was to evaluate the cost-
effectiveness of FCM versus no-treatment and oral iron supplementation in CHF 
patients with iron deficiency w/o anemia. MethOds: We developed a Cost-Utility-
Model to simulate disease progression in CHF patients using different strategies of 
iron deficiency management. Markov modelling techniques were used to estimate 
disease progression, based on health states, defined by NYHA classes and death. 
Monte Carlo simulation accounted for uncertainty. The model includes 5 states and 
monthly transitions. Probabilities were derived from clinical and epidemiological 
studies. The cohort definition was adapted from the FAIR-HF study. Direct costs 
(NYHA, inpatient, outpatient and iron treatment costs) from published sources were 
used and expressed in 2014 Euro from the payer’s perspective. QALYs and total costs 
were projected over a 4-year time horizon and discounted at 5% p.a. Results: 
Over a 4-year timeframe, costs and outcomes associated with FCM would amount 
to 18,797.39 € and 2.46 QALYs. Costs associated with oral treatment are 17,307.06 € 
and 2.37 QALYs (ICER per QUALY gained: € 16,921.62). Costs and outcomes associated 
with no-treatment are 17,934.15 € and 2.3 QALYs (ICER per QUALY gained: 5,411.23 € ). 
Due to a delayed disease progression in the FCM group NYHA costs are lower than 
with oral replacement and no-treatment. cOnclusiOns: Iv iron treatment with 
FCM compared with oral iron in iron deficient CHF patients is clearly below the CE 
threshold of € 22.200-€ 33.300/QUALY typically used by the UK NICE and hence can 
be considered a cost efficient treatment strategy.
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Objectives: Peripheral arterial disease entails increased mortality besides a sig-
nificant economic and humanistic burden, especially in patients with critical limb 
ischemia (CLI; stages III and IV). Prostanoids are usually indicated to those unsuit-
able for interventional therapy. We aimed to assess the overall costs of alprostadil 
(prostaglandin E1) as treatment for CLI compared with amputation from the per-
spective of the Instituto Mexicano del Seguro Social (IMSS). MethOds: Based on 
published literature, information derived from an expert panel, and local official 
sources of unit costs and other parameters, we evaluated three categories of costs: 
acquisition and administration of alprostadil given 40µg twice a day for 28 days; 
surgery, hospital stay, and rehabilitation after amputation; incapacity, prosthesis, 
and pensions in assumed current workers. We conducted the analysis for a time 
frame of one year using a decision tree developed in Microsoft Excel®. We gathered 
the effectiveness of alprostadil from a clinical trial. All costs are expressed in 2014 
Mexican pesos (MXN). We performed a deterministic sensitivity analysis. Results: 
Excluding the prosthesis costs, total direct medical costs of alprostadil were MXN 
4006 (5.8%) lower than the direct medical costs expected with limb amputation 
(MXN 65,490 Vs. MXN 69,496). When costs due to incapacity, prosthesis, and pensions 
in the workforce subpopulation were included into the analysis, the net difference 
in favour of alprostadil reached MXN 8,864 (MXN 66,577 Vs. MXN 75,441) which is 
equivalent to an overall cost reduction of 11.8%. Deterministic sensitivity analysis 
showed the model is quite sensitive to the acquisition and intra-arterial costs of 
alprostadil. cOnclusiOns: Acquisition and administration costs of alprostadil 
may be offset by the overall savings in direct medical costs and in payments due 
to incapacities and pensions.
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Objectives: Determining pharmacoeconomic efficiency of actovegin in complex 
therapy of complicated chronic venous disease of lower extremities. MethOds: 
old of £30,000. cOnclusiOns: At a willingness-to-pay threshold of £20,000 per 
QALY, all NOACs are cost-effective compared with warfarin. There is considerable 
uncertainty between the different NOACs, but apixaban (5mg bd) had the highest 
expected incremental net benefit and the highest probability (60%) of being most 
cost-effective first line anticoagulant for the prevention of stroke in AF, primarily 
due to lower rates of intracranial haemorrhage, other clinically relevant bleeding, 
and myocardial infarction.
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Objectives: To assess the cost-effectiveness of edoxaban versus acenocoumarol 
(VKA treatment) in the prevention of stroke and systemic embolic events in patients 
with non-valvular atrial fibrillation (NVAF) in Spain. MethOds: A Markov model 
was developed and adapted to the Spanish setting to simulate the evolution of 
NVAF patients throughout their lifetime. The Cycle length was 1 month and differ-
ent health states such as stroke, bleeding and other cardiovascular complications 
were defined to mimic NVAF natural history. Drug’s safety and efficacy outcomes 
were obtained from the Phase III trial. The analysis was conducted from the Spanish 
National Health System (NHS) perspective. Edoxaban and acenocoumarol costs were 
calculated according to recommended doses. The costs of NVAF complications and 
disease management costs were obtained from available Spanish published sources. 
An annual discount of 3% for costs and health outcomes was applied. Results: 
Edoxaban resulted on average with 0.337 quality-adjusted life-years (QALYs) gained 
and 0.285 life years gained (LYG) compared with acenocoumarol. Due to the pro-
jected longer survival of patients, edoxaban could generate more costs per patient 
than acenocoumarol from the NHS perspective, but the incremental cost-effective-
ness ratio (ICER) for edoxaban was highly cost effective, at 7,888€ per LYG and 6,671 € 
per QALY gained. To evaluate study robustness subgroup analyses (such CHADS2> 3 
score and percentage of well controlled patients), and probabilistic sensitivity analy-
ses were performed. Those analyses confirmed the ICERs for edoxaban to be cost-
effective when applying the commonly accepted cost effectiveness threshold in 
Spain. cOnclusiOns: Edoxaban is cost-effective compared with acenocoumarol 
from the NHS perspective in the prevention of stroke and systemic embolic events 
in patients with NVAF in Spain.
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Objectives: Deep venous thrombosis (DVT) and pulmonary embolism (PE) com-
prise venous thromboembolism (VTE), the third most common cardiovascular ill-
ness after acute coronary syndrome and stroke and a raising public health concern 
due to its morbity and mortality and higher costs. Acute and long term treatments 
help to avoid complications. We assessed the costs and effectiveness of different 
regimens for treatment of DVT without PE under the perspective of the Mexican 
public health system. MethOds: A seven-pathway decision tree allowed compari-
son of five competing strategies. Acute treatment for 7 days involved bemiparin 
115UI/Kg once daily (BEM), enoxaparin 1.5mg/Kg once daily (ENO-OAD), enoxaparin 
1.0 mg/Kg twice daily (ENO-BID), nadroparin 100UI/Kg twice daily (NAD) or unfrac-
tionated heparin administered as 80UI/Kg initial bolus followed by continuous 
infusion at a rate of 18/UI/Kg/hour (UFH). Long-term treatment consisted of daily 
doses of warfarin 5 mg given orally during 83 days (VKA). Direct medical costs 
included acquisition of medicines, care of further VTE episodes, and managing 
of adverse events/complications. Resource use was based on published literature 
and expert´s opinion. Local unit costs and diagnosis-related groups (DRG) costs 
were gathered. Effectiveness is expressed in terms of VTE-free patients and deaths 
avoided per 1000 treated. Deterministic and probabilistic sensitivity analyses were 
conducted. Results: Acute treatment with BEM was the most-effective interven-
tion with benefits ranging from 33 VTE-free patients and 7 deaths avoided (Vs. 
ENO-OAD and ENO-BID, respectively) to 64 VTE-free patients and 21 deaths avoided 
(both Vs. NAD) per 1,000 treated. BEM followed by warfarin was also the less costly 
regimen leading to overall cost-savings varying between MXN$3,067,626 (Vs. NFH) 
and MXN$7,084,142 (Vs. NAD) per 1,000 treated. Model results were robust to plau-
sible changes in main parameters. cOnclusiOns: Bemiparin may present a cost 
saving alternative over the use of other low molecular weight heparins or UFH as 
initial therapy for patients affected by DVT without PE.
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Objectives: The objectives of this systematic review were to identify published 
economic analyses of new oral anticoagulants (NOACs) for primary venous throm-
boembolism (VTE) prophylaxis following total hip replacement (THR) and total knee 
replacement (TKR) surgeries and to summarise the modelling techniques used and 
cost-effectiveness results. MethOds: Electronic searches of MEDLINE, EconLit, and 
the Cochrane Library were performed from January 2008 to February 2015 using a 
combination of Medical Subject Headings and free-text terms that were grouped 
into the following categories: population (including terms for thromboembolism 
and orthopaedic surgery), intervention (including terms for apixaban, dabigatran, 
edoxaban, and rivaroxaban), and study design (including terms for economic analy-
